Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model
Viruses · 2025
DOI: 10.3390/v17030342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Sandra L Bixler und 8 weiteren Autor:innen. Beteiligte Einrichtung: US Army Medical Research Institute of Infectious Diseases, Porter Street, Fort Detrick, MD 21702, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Ebola, Ebola Vaccines, Ebolavirus, Immunogenicity, Vaccine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Threat Reduction Agency (DTRA), Biomedical Advanced Research and Development Authority (BARDA), Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
The rVSVΔG-ZEBOV-GP vaccine demonstrated efficacy in preventing Ebola virus (EBOV) disease in a ring vaccination clinical trial conducted during the 2014–2016 West Africa outbreak and is licensed by regulatory agencies, including the US FDA and the EMA. Here, we present two studies that evaluated the durability of immunogenicity and protection from an EBOV challenge up to ~12 months following vaccination with rVSVΔG-ZEBOV-GP in nonhuman primates (NHPs). Cynomolgus macaques were vaccinated with either one or two doses of rVSVΔG-ZEBOV-GP or a saline control and were challenged intramuscularly with EBOV at a target dose of 1000 pfu at ~4 months (Study 1) or ~8 or ~12 months (Study 2) after the last vaccination. All vaccinated animals developed robust ZEBOV-GP-specific IgG and neutralizing antibody titers, which were sustained until the last time point tested prior to the challenge. The majority of animals (88–93%) challenged with EBOV at ~4 or ~8 months post-vaccination survived, whereas the survival rate was lower (53%) in animals challenged ~12 months post-vaccination. These results demonstrate that both one-dose and two-dose regimens of the rVSVΔG-ZEBOV-GP vaccine induced durable ZEBOV-GP-specific antibody titers in NHPs and provided high levels of protection against a lethal EBOV challenge up to ~8 months post-vaccination. In this stringent challenge model, decreased protection was observed at ~12 months post-vaccination despite sustained antibody levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- US Army Medical Research Institute of Infectious Diseases, Porter Street, Fort Detrick, MD 21702, USA.
- Merck & Co., Inc., Lincoln Ave., Rahway, NJ 07065, USA.
Förderung
- Defense Threat Reduction Agency (DTRA)
- Biomedical Advanced Research and Development Authority (BARDA)
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- HHS
- U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research and Development…
- Merck Sharp & Dohme LLC
Zitieren
APA
Bixler, S. L., Shurtleff, A. C., Sunay, M. M. E., Liu, K., Chen, Z., Eichberg, M., Simon, J. K., Coller, B. G., & Dubey, S. (2025). Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model. Viruses. https://doi.org/10.3390/v17030342
Vancouver
Bixler SL, Shurtleff AC, Sunay MME, Liu K, Chen Z, Eichberg M, et al. Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025. doi:10.3390/v17030342
BibTeX
@article{Bixler2025,
author = {Bixler, Sandra L and Shurtleff, Amy C and Sunay, Melek M E and Liu, Kenneth and Chen, Ziqiang and Eichberg, Michael and Simon, Jakub K and Coller, Beth-Ann G and Dubey, Sheri},
title = {Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17030342}
}
EUVIMED